{"transactions":[{"id":4618412,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:07:01.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1936,"price":156.22,"value":302441.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":22647,"source":{"system":"sec-edgar","filing":"0001894425-26-000020","document":"wk-form4_1789506418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000189442526000020/wk-form4_1789506418.xml","form_type":"4"}},{"id":4618411,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:07:01.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":3587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":24583,"source":{"system":"sec-edgar","filing":"0001894425-26-000020","document":"wk-form4_1789506418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000189442526000020/wk-form4_1789506418.xml","form_type":"4"}},{"id":4618409,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:06:39.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2419,"price":156.22,"value":377896.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":56793,"source":{"system":"sec-edgar","filing":"0001504783-26-000019","document":"wk-form4_1789506394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1504783/000150478326000019/wk-form4_1789506394.xml","form_type":"4"}},{"id":4618408,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:06:39.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":4483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":59212,"source":{"system":"sec-edgar","filing":"0001504783-26-000019","document":"wk-form4_1789506394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1504783/000150478326000019/wk-form4_1789506394.xml","form_type":"4"}},{"id":4618405,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41469,"kind":"person","name":"Keswani Sanjay Chandru","position":1,"cik":"0001818524","reported_name":"Keswani Sanjay Chandru","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:55.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2112,"price":156.22,"value":329936.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":3281,"source":{"system":"sec-edgar","filing":"0001818524-26-000006","document":"wk-form4_1789506353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818524/000181852426000006/wk-form4_1789506353.xml","form_type":"4"}},{"id":4618404,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41469,"kind":"person","name":"Keswani Sanjay Chandru","position":1,"cik":"0001818524","reported_name":"Keswani Sanjay Chandru","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:55.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":3914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":5393,"source":{"system":"sec-edgar","filing":"0001818524-26-000006","document":"wk-form4_1789506353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818524/000181852426000006/wk-form4_1789506353.xml","form_type":"4"}},{"id":4618399,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:05:32.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":7839,"price":156.22,"value":1224608.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power."}],"balance_after":517797,"source":{"system":"sec-edgar","filing":"0001201096-26-000018","document":"wk-form4_1789506329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000018/wk-form4_1789506329.xml","form_type":"4"}},{"id":4618398,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T21:05:32.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":14343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":525636,"source":{"system":"sec-edgar","filing":"0001201096-26-000018","document":"wk-form4_1789506329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201096/000120109626000018/wk-form4_1789506329.xml","form_type":"4"}},{"id":4618397,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":994,"price":156.22,"value":155282.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":154728,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618396,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":1842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":155722,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618395,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":3386,"price":156.22,"value":528960.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":153880,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618394,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":66313,"kind":"person","name":"Gano Kyle","position":1,"cik":"0001567160","reported_name":"Gano Kyle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:05:05.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":6275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":157266,"source":{"system":"sec-edgar","filing":"0001567160-26-000009","document":"wk-form4_1789506302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567160/000156716026000009/wk-form4_1789506302.xml","form_type":"4"}},{"id":4618379,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:04:05.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2419,"price":156.22,"value":377896.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":18289,"source":{"system":"sec-edgar","filing":"0001965808-26-000015","document":"wk-form4_1789506243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1965808/000196580826000015/wk-form4_1789506243.xml","form_type":"4"}},{"id":4618378,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:04:05.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":4483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":20708,"source":{"system":"sec-edgar","filing":"0001965808-26-000015","document":"wk-form4_1789506243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1965808/000196580826000015/wk-form4_1789506243.xml","form_type":"4"}},{"id":4618377,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:43.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1936,"price":156.22,"value":302441.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power."}],"balance_after":24025,"source":{"system":"sec-edgar","filing":"0001776977-26-000013","document":"wk-form4_1789506221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776977/000177697726000013/wk-form4_1789506221.xml","form_type":"4"}},{"id":4618376,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:43.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":3587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":25961,"source":{"system":"sec-edgar","filing":"0001776977-26-000013","document":"wk-form4_1789506221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776977/000177697726000013/wk-form4_1789506221.xml","form_type":"4"}},{"id":4618375,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":826,"price":157.4462,"value":130050.5612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":8722,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":4618374,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":1936,"price":156.22,"value":302441.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":9548,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":4618373,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-11","kind":"grant","planned":true,"acquired":true,"shares":3587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":11484,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":4618360,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:46.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":3386,"price":156.22,"value":528960.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":67297,"source":{"system":"sec-edgar","filing":"0001643653-26-000018","document":"wk-form4_1789506163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000018/wk-form4_1789506163.xml","form_type":"4"}},{"id":4618359,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:46.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":6275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":70683,"source":{"system":"sec-edgar","filing":"0001643653-26-000018","document":"wk-form4_1789506163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000018/wk-form4_1789506163.xml","form_type":"4"}},{"id":4618358,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":2311,"price":157.1981,"value":363284.8091,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42808,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":4618357,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":2709,"price":156.22,"value":423199.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":45119,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":4618356,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:02:22.000Z","date":"2026-09-11","kind":"grant","planned":true,"acquired":true,"shares":5020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":47828,"source":{"system":"sec-edgar","filing":"0001724097-26-000010","document":"wk-form4_1789506139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724097/000172409726000010/wk-form4_1789506139.xml","form_type":"4"}},{"id":4615474,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Incentive Stock Option","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":3194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.  These options were due to expire on February 6, 2027."}],"balance_after":0,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":3194},"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":4615473,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":2154,"price":154.61,"value":333029.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":64408,"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":4615472,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":47613,"kind":"person","name":"BENEVICH ERIC","position":1,"cik":"0001643653","reported_name":"BENEVICH ERIC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T00:29:07.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":3194,"price":43.24,"value":138108.56,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":66562,"source":{"system":"sec-edgar","filing":"0001643653-26-000016","document":"wk-form4_1789086545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643653/000164365326000016/wk-form4_1789086545.xml","form_type":"4"}},{"id":4053,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T01:39:55.000Z","date":"2026-09-02","kind":"gift","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":14860,"source":{"system":"sec-edgar","filing":"0001079462-26-000008","document":"wk-form4_1788485992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1079462/000107946226000008/wk-form4_1788485992.xml","form_type":"4"}},{"id":696278,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T21:35:50.000Z","date":"2026-08-04","kind":"gift","planned":false,"acquired":false,"shares":2409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective August 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":20996,"source":{"system":"sec-edgar","filing":"0001894425-26-000018","document":"wk-form4_1785965748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000018/wk-form4_1785965748.xml","form_type":"4"}},{"id":701003,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-30T21:29:11.000Z","date":"2026-07-29","kind":"exercise","planned":true,"acquired":false,"shares":842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vested in 12 monthly installments beginning June 22, 2024."}],"balance_after":2140,"derivative":{"exercise_price":139.43,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":842},"source":{"system":"sec-edgar","filing":"0001533568-26-000012","document":"wk-form4_1785446949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000012/wk-form4_1785446949.xml","form_type":"4"}},{"id":701002,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-30T21:29:11.000Z","date":"2026-07-29","kind":"exercise","planned":true,"acquired":true,"shares":842,"price":139.43,"value":117400.06,"ownership":{"direct":true},"balance_after":2430,"source":{"system":"sec-edgar","filing":"0001533568-26-000012","document":"wk-form4_1785446949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000012/wk-form4_1785446949.xml","form_type":"4"}},{"id":701001,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-30T21:29:11.000Z","date":"2026-07-28","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":182.006,"value":227507.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1588,"source":{"system":"sec-edgar","filing":"0001533568-26-000012","document":"wk-form4_1785446949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000012/wk-form4_1785446949.xml","form_type":"4"}},{"id":710857,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-13T20:27:43.000Z","date":"2026-07-10","kind":"exercise","planned":true,"acquired":false,"shares":4367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":106.02,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":4367},"source":{"system":"sec-edgar","filing":"0001965808-26-000013","document":"wk-form4_1783974461.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000013/wk-form4_1783974461.xml","form_type":"4"}},{"id":710856,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:27:43.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":4367,"price":181.02,"value":790514.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":16225,"source":{"system":"sec-edgar","filing":"0001965808-26-000013","document":"wk-form4_1783974461.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000013/wk-form4_1783974461.xml","form_type":"4"}},{"id":710855,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:27:43.000Z","date":"2026-07-10","kind":"exercise","planned":true,"acquired":true,"shares":4367,"price":106.02,"value":462989.34,"ownership":{"direct":true},"balance_after":20592,"source":{"system":"sec-edgar","filing":"0001965808-26-000013","document":"wk-form4_1783974461.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000013/wk-form4_1783974461.xml","form_type":"4"}},{"id":710854,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-13T20:27:09.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."}],"balance_after":4965,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001504783-26-000017","document":"wk-form4_1783974426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000017/wk-form4_1783974426.xml","form_type":"4"}},{"id":710853,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:27:09.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":179.6014,"value":1796014.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54729,"source":{"system":"sec-edgar","filing":"0001504783-26-000017","document":"wk-form4_1783974426.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000017/wk-form4_1783974426.xml","form_type":"4"}},{"id":710852,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:27:09.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":81.49,"value":814900.0,"ownership":{"direct":true},"balance_after":64729,"source":{"system":"sec-edgar","filing":"0001504783-26-000017","document":"wk-form4_1783974426.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000017/wk-form4_1783974426.xml","form_type":"4"}},{"id":712187,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":8433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023."}],"balance_after":7478,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":8433},"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712186,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":2737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023."}],"balance_after":15911,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":2737},"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712185,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":3401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023."}],"balance_after":18648,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":3401},"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712184,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":8433,"price":178.7187,"value":1507134.7971,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16225,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712183,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":8433,"price":103.52,"value":872984.16,"ownership":{"direct":true},"balance_after":24658,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712182,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":2737,"price":178.543,"value":488672.191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16225,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712181,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":2737,"price":103.52,"value":283334.24,"ownership":{"direct":true},"balance_after":18962,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712180,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":3401,"price":178.5666,"value":607305.0066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16225,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":712179,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-07-09T22:41:02.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":3401,"price":103.52,"value":352071.52,"ownership":{"direct":true},"balance_after":19626,"source":{"system":"sec-edgar","filing":"0001965808-26-000011","document":"wk-form4_1783636859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000011/wk-form4_1783636859.xml","form_type":"4"}},{"id":723226,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":1690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."}],"balance_after":14965,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":1690},"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723225,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":8110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."}],"balance_after":16655,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":8110},"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723224,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."}],"balance_after":24765,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723223,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1690,"price":170.8144,"value":288676.336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54729,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723222,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":1690,"price":81.49,"value":137718.1,"ownership":{"direct":true},"balance_after":56419,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723221,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":8110,"price":170.025,"value":1378902.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54729,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723220,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":8110,"price":81.49,"value":660883.9,"ownership":{"direct":true},"balance_after":62839,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723219,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":200,"price":169.565,"value":33913.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54729,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":723218,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30876,"kind":"person","name":"Lippoldt Darin","position":1,"cik":"0001504783","reported_name":"Lippoldt Darin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:52:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":81.49,"value":16298.0,"ownership":{"direct":true},"balance_after":54929,"source":{"system":"sec-edgar","filing":"0001504783-26-000015","document":"wk-form4_1782852730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000150478326000015/wk-form4_1782852730.xml","form_type":"4"}},{"id":745359,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted May 22, 2019 and vested in 12 equal monthly installments beginning June 22, 2019."}],"balance_after":0,"derivative":{"exercise_price":79.79,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745358,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017."}],"balance_after":0,"derivative":{"exercise_price":53.64,"expiration_date":"2027-05-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745357,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":1843,"price":167.3128,"value":308357.4904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.11 to $167.70.  The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15860,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745356,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":5829,"price":166.5567,"value":970859.0043,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.11 to $167.09.  The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":17703,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745355,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":6896,"price":165.7926,"value":1143305.7696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.11 to $166.09.  The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23532,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745354,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":2549,"price":164.4394,"value":419156.0306,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.11 to $164.83.  The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30428,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745353,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7883,"price":163.807,"value":1291290.581,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.11 to $164.10.  The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32977,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745352,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":79.79,"value":797900.0,"ownership":{"direct":true},"balance_after":40860,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745351,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:40:34.000Z","date":"2026-06-05","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":53.64,"value":804600.0,"ownership":{"direct":true},"balance_after":30860,"source":{"system":"sec-edgar","filing":"0001079462-26-000006","document":"wk-form4_1781041231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000006/wk-form4_1781041231.xml","form_type":"4"}},{"id":745350,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-09T21:34:43.000Z","date":"2026-06-05","kind":"gift","planned":false,"acquired":false,"shares":2441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective June 5, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":23405,"source":{"system":"sec-edgar","filing":"0001894425-26-000014","document":"wk-form4_1781040880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000014/wk-form4_1781040880.xml","form_type":"4"}},{"id":746934,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:07:54.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":168.0573,"value":210071.625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy\nrestricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":2838,"source":{"system":"sec-edgar","filing":"0001533568-26-000009","document":"wk-form4_1780956471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000009/wk-form4_1780956471.xml","form_type":"4"}},{"id":750181,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":false,"shares":24965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."}],"balance_after":0,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":24965},"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750180,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":3520,"price":158.5897,"value":558235.744,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.  Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.26 to $158.91.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"20,334 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power."}],"balance_after":22374,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750179,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":9521,"price":157.6161,"value":1500662.8881,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.  Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.26 to $158.25.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25894,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750178,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":4216,"price":156.766,"value":660925.456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.  Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $156.26 to $157.25.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":35415,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750177,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":5466,"price":155.4566,"value":849725.7756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.  Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.20 to $156.19.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":39631,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750176,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":14214,"price":154.8252,"value":2200685.3928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.  Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.20 to $155.19.  The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":45097,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750175,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41470,"kind":"person","name":"Cooke Julie","position":1,"cik":"0001776977","reported_name":"Cooke Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2026-06-04T22:02:44.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":true,"shares":24965,"price":81.49,"value":2034397.85,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":59311,"source":{"system":"sec-edgar","filing":"0001776977-26-000010","document":"wk-form4_1780610561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000177697726000010/wk-form4_1780610561.xml","form_type":"4"}},{"id":750173,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41469,"kind":"person","name":"Keswani Sanjay Chandru","position":1,"cik":"0001818524","reported_name":"Keswani Sanjay Chandru","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-04T21:54:17.000Z","date":"2026-06-02","kind":"exercise","planned":false,"acquired":false,"shares":3212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU was granted to the Reporting Person on June 2, 2025. In accordance with the terms of the RSU, the award vested as to 3,212 shares on June 2, 2026, and will vest as to 3,212 shares on June 2, 2027, 3,211 shares on June 2, 2028, and 3,211 shares on June 2, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU was granted to the Reporting Person on June 2, 2025. In accordance with the terms of the RSU, the award vested as to 3,212 shares on June 2, 2026, and will vest as to 3,212 shares on June 2, 2027, 3,211 shares on June 2, 2028, and 3,211 shares on June 2, 2029, subject to the terms and conditions of the award."}],"balance_after":9634,"derivative":{"underlying":"Common Stock","underlying_shares":3212},"source":{"system":"sec-edgar","filing":"0001818524-26-000004","document":"wk-form4_1780610055.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000181852426000004/wk-form4_1780610055.xml","form_type":"4"}},{"id":750172,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41469,"kind":"person","name":"Keswani Sanjay Chandru","position":1,"cik":"0001818524","reported_name":"Keswani Sanjay Chandru","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T21:54:17.000Z","date":"2026-06-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1733,"price":154.84,"value":268337.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":1479,"source":{"system":"sec-edgar","filing":"0001818524-26-000004","document":"wk-form4_1780610055.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000181852426000004/wk-form4_1780610055.xml","form_type":"4"}},{"id":750171,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":41469,"kind":"person","name":"Keswani Sanjay Chandru","position":1,"cik":"0001818524","reported_name":"Keswani Sanjay Chandru","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T21:54:17.000Z","date":"2026-06-02","kind":"exercise","planned":false,"acquired":true,"shares":3212,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3212,"source":{"system":"sec-edgar","filing":"0001818524-26-000004","document":"wk-form4_1780610055.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000181852426000004/wk-form4_1780610055.xml","form_type":"4"}},{"id":755919,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested\nand exercisable each month thereafter."}],"balance_after":13268,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":755918,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":11000,"price":160.2464,"value":1762710.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25846,"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":755917,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":11000,"price":84.74,"value":932140.0,"ownership":{"direct":true},"balance_after":36846,"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":755916,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-02T22:03:14.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":false,"shares":2261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022."}],"balance_after":0,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":2261},"source":{"system":"sec-edgar","filing":"0001965808-26-000007","document":"wk-form4_1780437791.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000007/wk-form4_1780437791.xml","form_type":"4"}},{"id":755915,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:03:14.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":2261,"price":156.71,"value":354321.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":16225,"source":{"system":"sec-edgar","filing":"0001965808-26-000007","document":"wk-form4_1780437791.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000007/wk-form4_1780437791.xml","form_type":"4"}},{"id":755914,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":30877,"kind":"person","name":"Delaet Ingrid","position":1,"cik":"0001965808","reported_name":"Delaet Ingrid","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:03:14.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":true,"shares":2261,"price":79.02,"value":178664.22,"ownership":{"direct":true},"balance_after":18486,"source":{"system":"sec-edgar","filing":"0001965808-26-000007","document":"wk-form4_1780437791.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000196580826000007/wk-form4_1780437791.xml","form_type":"4"}},{"id":759338,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter."}],"balance_after":24268,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":759337,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":11000,"price":155.5332,"value":1710865.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25846,"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":759336,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":true,"shares":11000,"price":84.74,"value":932140.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":36846,"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":759327,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":31405,"kind":"person","name":"GORMAN KEVIN CHARLES","position":1,"cik":"0001201096","reported_name":"GORMAN KEVIN CHARLES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:05:50.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in 12 monthly installments beginning June 27, 2026."}],"balance_after":5248,"derivative":{"exercise_price":155.83,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":5248},"source":{"system":"sec-edgar","filing":"0001201096-26-000012","document":"wk-form4_1780092347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120109626000012/wk-form4_1780092347.xml","form_type":"4"}},{"id":759326,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43292,"kind":"person","name":"POPS RICHARD F","position":1,"cik":"0001126490","reported_name":"POPS RICHARD F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:05:11.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001126490-26-000005","document":"wk-form4_1780092309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112649026000005/wk-form4_1780092309.xml","form_type":"4"}},{"id":759325,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:04:49.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 27, 2026."}],"balance_after":2624,"derivative":{"exercise_price":155.83,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":2624},"source":{"system":"sec-edgar","filing":"0001123343-26-000008","document":"wk-form4_1780092285.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000008/wk-form4_1780092285.xml","form_type":"4"}},{"id":759324,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:04:49.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":1284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":1284,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1284},"source":{"system":"sec-edgar","filing":"0001123343-26-000008","document":"wk-form4_1780092285.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000112334326000008/wk-form4_1780092285.xml","form_type":"4"}},{"id":759323,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14289,"kind":"person","name":"Mercier Johanna","position":1,"cik":"0001782135","reported_name":"Mercier Johanna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:04:22.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001782135-26-000020","document":"wk-form4_1780092260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000178213526000020/wk-form4_1780092260.xml","form_type":"4"}},{"id":759322,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":13319,"kind":"person","name":"POON CHRISTINE A","position":1,"cik":"0001189014","reported_name":"POON CHRISTINE A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:03:51.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001189014-26-000007","document":"wk-form4_1780092228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000118901426000007/wk-form4_1780092228.xml","form_type":"4"}},{"id":759321,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":34427,"kind":"person","name":"Sharp Shalini","position":1,"cik":"0001377202","reported_name":"Sharp Shalini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:03:31.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001377202-26-000006","document":"wk-form4_1780092209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000137720226000006/wk-form4_1780092209.xml","form_type":"4"}},{"id":759320,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:03:06.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001079462-26-000004","document":"wk-form4_1780092183.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000004/wk-form4_1780092183.xml","form_type":"4"}},{"id":759319,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":13164,"kind":"person","name":"MORROW GEORGE J","position":1,"cik":"0001068754","reported_name":"MORROW GEORGE J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:02:40.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001068754-26-000004","document":"wk-form4_1780092157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000106875426000004/wk-form4_1780092157.xml","form_type":"4"}},{"id":759316,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:02:12.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":2567,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2567},"source":{"system":"sec-edgar","filing":"0001205903-26-000004","document":"wk-form4_1780092129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120590326000004/wk-form4_1780092129.xml","form_type":"4"}},{"id":759315,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:01:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in 12 monthly installments beginning June 27, 2026."}],"balance_after":2624,"derivative":{"exercise_price":155.83,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":2624},"source":{"system":"sec-edgar","filing":"0001533568-26-000007","document":"wk-form4_1780092090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000007/wk-form4_1780092090.xml","form_type":"4"}},{"id":759314,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":14658,"kind":"person","name":"Norwalk Leslie V","position":1,"cik":"0001533568","reported_name":"Norwalk Leslie V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restriced Stock Unit","published_at":"2026-05-29T22:01:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":1284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":1284,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1284},"source":{"system":"sec-edgar","filing":"0001533568-26-000007","document":"wk-form4_1780092090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000153356826000007/wk-form4_1780092090.xml","form_type":"4"}},{"id":760741,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-05-28T22:08:59.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":3888,"price":156.6418,"value":609023.3184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":7799,"source":{"system":"sec-edgar","filing":"0001909817-26-000007","document":"wk-form4_1780006136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000007/wk-form4_1780006136.xml","form_type":"4"}},{"id":768861,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":2656,"kind":"person","name":"SHERWIN STEPHEN A","position":1,"cik":"0001079462","reported_name":"SHERWIN STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T23:24:56.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001079462-26-000002","document":"wk-form4_1779405893.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000107946226000002/wk-form4_1779405893.xml","form_type":"4"}}],"next_cursor":"2026-05-21T23:24:56.000000Z,768861"}